

This is an update about information in the provider manual. For access to the latest provider manual, go online to <https://providers.amerigroup.com>.

Quarterly pharmacy formulary change notice

Summary of change: The formulary changes listed in the table below were reviewed and approved at our September 27, 2016, Pharmacy and Therapeutics Committee meeting.

What this means to you

Effective February 1, 2017, the changes outlined below apply to all Amerigroup Community Care members. **Don't forget to read the footnotes at the bottom of the table.**

What is the impact of this change?

Effective for all patients on February 1, 2017			
Therapeutic class	Drug	Revised status	Potential alternatives
INSULIN THERAPY — LONG-ACTING*	BASAGLAR KWIKPEN	PREFERRED	N/A
INSULIN THERAPY — LONG-ACTING	LANTUS 100 UNITS/ML VIAL LANTUS SOLOSTAR 100 UNITS/ML	NONPREFERRED NEW STARTS: 02/01/17 CURRENT UTILIZERS: 05/01/17	BASAGLAR KWIKPEN
ACNE — BENZOYL PEROXIDE COMBOS	CLIND PH-BENZOYL PEROX 1.2-5% CLINDAMYCIN-BENZOYL PEROX 1-5% CLINDA-BENZOYL PEROX 1-5% PUMP	PREFERRED	N/A
ACNE — BENZOYL PEROXIDE COMBOS	ERYTHROMYCIN-BENZOYL GEL	NONPREFERRED STEP THERAPY (ST) REQUIRED	CLINDAMYCIN-BENZOYL PEROX 1-5% GEL
ACNE THERAPY	ERYTHROMYCIN/BENZOYL PEROXIDE ACANYA GEL PUMP ONEXTON GEL PUMP BENZACLIN GEL BENZAMYCIN GEL DUAC GEL	STEP THERAPY (AN APPROVAL FOR NONPREFERRED AGENTS WILL BE CONSIDERED WHERE CLINDAMYCIN/BENZOYL PEROXIDE GEL IS NOT APPROPRIATE BASED ON A MEMBERS HISTORY OF MEDICAL CONDITIONS)	CLINDAMYCIN-BENZOYL PEROX 1-5% GEL
ANDROGENS	TESTOSTERONE 25 MG/2.5 GM PKT	ADD QUANTITY LIMIT (QL)	N/A
ANTI-EMETICS	EMEND	NONPREFERRED PRIOR AUTHORIZATION (PA) REQUIRED	N/A

<https://providers.amerigroup.com>

Effective for all patients on February 1, 2017			
ANTINEOPLASTIC AGENTS	TECENTRIQ 1,200 MG/20 ML VIAL	ADD QL	N/A
ANTIVIRALS — MISCELLANEOUS	RELENZA 5 MG DISKHALER TAMIFLU SUSPENSION TAMIFLU CAPSULES	REVISED QL	N/A
EMERGENCY CONTRACEPTIVES	ELLA 30 MG TABLET REACT 1.5 MG TABLET	PREFERRED	N/A
EPINEPHRINE — SELF-INJECTED*	EPINEPHRINE 0.15 MG AUTO-INJECT EPINEPHRINE 0.3 MG AUTO-INJECT EPINEPHRINE 0.1 MG/ML SYRINGE EPINEPHRINE 1 MG/ML VIAL	PREFERRED	N/A
EYE ANTI-INFLAMMATORY AGENTS	DICLOFENAC 0.1% EYE DROPS	PREFERRED	N/A
EYE ANTI-INFLAMMATORY AGENTS	KETOROLAC 0.4% OPHTH SOLUTION KETOROLAC 0.5% OPHTH SOLUTION ACUVAIL 0.45% OPHTH SOLUTION	NONPREFERRED ST REQUIRED	DICLOFENAC 0.1% EYE DROPS
GASTROINTESTINAL AGENTS — MISCELLANEOUS	APRISO ER 0.375 GRAM CAPSULE AZULFIDINE 500 MG TABLET AZULFIDINE ENTAB 500 MG CANASA 1,000 MG SUPPOSITORY DELZICOL DR 400 MG CAPSULE DIPENTUM 250 MG CAPSULE ENTOCORT EC 3 MG CAPSULE GIAZO 1.1 GM TABLET LIALDA DR 1.2 GM TABLET PENTASA 250 MG CAPSULE PENTASA 500 MG CAPSULE ROWASA 4 GM/60 ML ENEMA KIT SFROWASA 4 GM/60 ML ENEMA UCERIS 9 MG ER TABLET	ADD QL	N/A
HEPARIN AND RELATED PREPARATIONS	FRAGMIN INJ LOVENOX INJ	ADD QL	N/A
LANCETS	MANUFACTURER: US DIAGNOSTICS LANCETS MIS 28G LANCETS MIS 30G SAFETY MIS LANCETS	NONPREFERRED	LANCETS: MANUFACTURER — TARGET WALGREENS CVS CHAIN DRUG CONS GOOD NEIGHBOR KROGER/PERRIGO

Effective for all patients on February 1, 2017			
LIPID/CHOLESTEROL — LOWERING AGENTS	NIACOR 500 MG TABLET	ADD QL	N/A
NEUROLOGICAL THERAPY — MISCELLANEOUS	NAMZARIC 7 MG-10 MG CAPSULE NAMZARIC 21 MG-10 MG CAPSULE	ADD QL	N/A
OPHTHALMOLOGICS — MISCELLANEOUS	RESTASIS 0.05% EYE EMULSION	ADD QL	N/A
OPHTHALMOLOGICS — MISCELLANEOUS	XIIDRA 5% EYE DROPS LACRISERT 5 MG EYE INSERT	ADD QL	N/A
ORAL HYPOGLYCEMIC AGENTS	JENTADUETO XR 2.5 MG-1,000 MG JENTADUETO XR 5 MG-1,000 MG TB	ADD QL	N/A
ORAL SKELETAL MUSCLE RELAXANTS	TIZANIDINE HCL 2 MG CAPSULE TIZANIDINE HCL 4 MG CAPSULE TIZANIDINE HCL 6 MG CAPSULE	NONPREFERRED	TIZANIDINE HCL 2 MG TABLET TIZANIDINE HCL 4 MG TABLET
OTIC STEROID/ ANTIBIOTIC	FLOXIN 0.3% EAR DROPS	PREFERRED	N/A
OTIC STEROID/ ANTIBIOTIC	CIPRODEX OTIC SUSPENSION CORTISPORIN-TC OTIC	NONPREFERRED WITH ST	FLOXIN 0.3% EAR DROPS CIPROFLOXACIN 0.2% OTIC SOLN OFLOXACIN 0.3% EAR DROPS NEOMYCIN-POLYMYXIN- HC EAR SOLN

** These changes will be effective immediately upon the release of the epinephrine authorized generic release and Basaglar release.*

What action do I need to take?

Please review these changes and work with your Amerigroup patients to transition them to formulary alternatives. If you determine preferred formulary alternatives are not clinically appropriate for specific patients, you will need to obtain PA to continue coverage beyond the applicable effective date.

What if I need assistance?

We recognize the unique aspects of patients’ cases. If your Amerigroup patient cannot be converted to a formulary alternative for medical reasons, call our Pharmacy department at 1-800-454-3730 and follow the voice prompts for pharmacy PA. You can find the *Preferred Drug List* on our provider website at <https://providers.amerigroup.com/NJ>.

If you need assistance with any other item, contact your local Provider Relations representative or call Provider Services at 1-800-454-3730.